tiprankstipranks
Trending News
More News >

Innovotech Secures Funding to Advance Antimicrobial Testing and Product Development

Story Highlights
  • Innovotech Labs receives $150,000 CAD to develop new antimicrobial testing services.
  • Funding will enhance technical capabilities and improve health outcomes by reducing infections.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Protect Your Portfolio Against Market Uncertainty

Innovotech ( (TSE:IOT) ) has issued an announcement.

Innovotech Inc. announced that its subsidiary, Innovotech Labs Corporation, has secured up to $150,000 CAD in funding from the NRC IRAP to develop new antimicrobial testing services for medical devices, aligning with changing international standards. Additionally, the company will receive $30,000 CAD to hire a young graduate for developing antimicrobial silver compounds. This support is expected to enhance Innovotech’s technical capabilities, address customer needs, and improve health outcomes by reducing infections and complications.

More about Innovotech

Innovotech Inc. is a diversified Canadian technology company involved in specialized laboratory services, biotechnology, and proprietary intellectual property. It operates through subsidiaries like Innovotech Labs Corporation, which provides antimicrobial testing devices and solutions, and Keystone Labs Inc., serving the pharmaceutical and industrial markets. Innovotech also holds a stake in NouLife Sciences Inc., focusing on antioxidant molecules for cosmetics and medical applications.

Average Trading Volume: 23,549

Technical Sentiment Signal: Sell

Current Market Cap: C$7.21M

Find detailed analytics on IOT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App